Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07598357 · ClinicalTrials.gov registry record · NA
Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations
A NA study, sponsored by NYU Langone Health.
- Not yet
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT07598357 is a NA study that has not yet begun recruiting, run by NYU Langone Health. The registered enrollment target is 40 participants.
The verdict
NCT07598357, a NA study, has not yet begun recruiting, sponsored by NYU Langone Health.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to prospectively study the safety of salvage red blood cell (sRBC) transfusion during pancreatic surgery. Primary Objective: 1. To summarize rates and timing of septic adverse events (AE) for patients who receive sRBC or aRBC transfusions within 72 hours of peri-operative transfusion. 2. To summarize rates and timing of transfusion related AEs for patients who receive sRBC or aRBC transfusions within 72 hours of peri-operative transfusion. 3. To summarize rates and timing of AEs in the first 7 post-operative days. Secondary Objectives: 1. To summarize the number of units of aRBC transfused post operative day (POD) #0 after sRBC transfusion in the operating room. 2. To summarize the number of units of aRBC transfused POD#1-7 after sRBC transfusion the operating room, in the absence of overt post-operative hemorrhage.
Interventions
- DEVICE The Fresenius Kabi C.A.T.S®plus Continuous AutoTransfusion System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-06 |
| Est. Completion | 2031-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07598357
The ClinicalTrials.gov registry entry for NCT07598357 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which The Fresenius Kabi C.A.T.S®plus Continuous AutoTransfusion System is the first listed.
NCT07598357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07598357 about?
NCT07598357 is a clinical study titled "Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations". The purpose of this study is to prospectively study the safety of salvage red blood cell (sRBC) transfusion during pancreatic surgery. Primary Objective: 1. To summarize rates and timing of septic adverse events (AE) for patients who receive sRBC or aRBC transfusions within 72 hours of peri-operat...
What is the current status of trial NCT07598357?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2026-06. Estimated completion is 2031-06.
What interventions are being tested in trial NCT07598357?
The interventions under investigation include: The Fresenius Kabi C.A.T.S®plus Continuous AutoTransfusion System (DEVICE).
Who is sponsoring clinical trial NCT07598357?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.